About CellCarta
CellCarta is a company based in Montreal (Canada) founded in 2000 was acquired by Arsenal Capital Partners in July 2019. CellCarta has raised $7.5 million across 4 funding rounds from investors including Waters Corporation, HHS and Arsenal Capital Partners. CellCarta has completed 7 acquisitions, including Biogazelle, Clinical Logistics and ImmuneHealth. CellCarta offers products and services including CellEngine® Software, Immune Monitoring, Genomics Services, and Histopathology Services. CellCarta operates in a competitive market with competitors including Blue Rock Therapeutics, Impel Pharmaceuticals, Ascend, RiboPro and Invivyd, among others.
- Headquarter Montreal, Canada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.5 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
Waters Corporation
& 6 more
-
Employee Count
Not available
-
Investments & Acquisitions
Biogazelle
& 6 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CellCarta
CellCarta offers a comprehensive portfolio of products and services, including CellEngine® Software, Immune Monitoring, Genomics Services, and Histopathology Services.
Cytometry analysis tool for research and data processing in labs.
Assesses immune responses through various cellular assays and tests.
Offers DNA sequencing and PCR for therapeutic development applications.
Provides tissue analysis and digital pathology for medical research.
People of CellCarta
Unlock access to complete
Unlock access to complete
Funding Insights of CellCarta
CellCarta has successfully raised a total of $7.5M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CellCarta
CellCarta has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Waters Corporation, HHS and Arsenal Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on company buyouts
|
Locked | Locked | Locked | |
|
Private equity investments target specialty industrials and healthcare sectors.
|
Locked | Locked | Locked | |
|
Specialist healthcare investment advisory services are provided by GHO Capital.
|
Locked | Locked | Locked |
Investor details for CellCarta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CellCarta
CellCarta has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Biogazelle, Clinical Logistics and ImmuneHealth.
Investment portfolio details for CellCarta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pathology services and solutions are provided for researchers.
|
Locked | Locked | 2012 | Locked | |
|
Multi-parameter cell analysis systems are developed for high-content screening.
|
Locked | Locked | 2008 | Locked | |
|
Immune responses to cancer immunotherapies in clinical trials are monitored.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for CellCarta
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - CellCarta
Detailed financials for CellCarta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellcarta Comparisons
Peer comparison for CellCarta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CellCarta
CellCarta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Blue Rock Therapeutics, Impel Pharmaceuticals, Ascend, RiboPro and Invivyd, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| Locked | Locked | Locked |
Transformative therapies are developed and commercialized through specialized services.
|
|
| Locked | Locked | Locked |
Online insurance payments and premium financing are enabled for businesses.
|
|
| Locked | Locked | Locked |
Online supplier and developer of RNA based products
|
|
| Locked | Locked | Locked |
Stem cell drug research and clinical trial services are provided.
|
Detailed competitors of CellCarta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellcarta
Complete news archive for CellCarta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CellCarta
CellCarta was founded in 2000 and raised its 1st funding round 7 years after it was founded.
CellCarta is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
David Spaight is the current CEO of CellCarta.
CellCarta is a funded company, having raised a total of $7.5M across 4 funding rounds to date.
Founded in 2000 and based in Montreal, Canada, CellCarta operates as a contract research organization in the biotechnology sector. A range of services is provided, including histopathology, genomics, biomarker platforms, antigen presentation, bioanalytical solutions, bioinformatics, data mining, biologics characterization, and immune profiling. Access to these offerings supports research and development needs in the industry.
CellCarta's top competitors include Blue Rock Therapeutics, Ascend and RiboPro.
CellCarta offers CellEngine® Software, Immune Monitoring, Genomics Services, and Histopathology Services.
CellCarta has made 7 acquisitions, including Biogazelle, Clinical Logistics, and ImmuneHealth.
CellCarta has 7 investors. Key investors include Waters Corporation, HHS, Arsenal Capital Partners, The Michael J. Fox Foundation, and Great Point Partners.